New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN)
Analysts have significantly upgraded Septerna, Inc.'s revenue forecasts for 2026, boosting expectations from US$66m to US$74m. This indicates a more optimistic outlook for the company's sales pipeline. Despite a projected slowdown in revenue growth compared to historical performance, the market's positive reaction and the analysts' revised estimates suggest a potential for continued stock momentum.
New Forecasts: Here's What Analysts Think The Future Holds For Septerna, Inc. (NASDAQ:SEPN)
Analysts have significantly upgraded their revenue forecasts for Septerna, Inc. (NASDAQ:SEPN) for 2026, leading to a substantial increase from previously expected figures. The revised consensus now projects US$74 million in revenue, a 2.5% increase from the prior year, indicating a more optimistic outlook despite a projected slowdown in revenue growth compared to past performance and the wider industry. Investors reacted positively to the news, pushing the stock up 13% over the past week.
Why Septerna (SEPN) Is Up 11.6% After Q1 Revenue Surge And Narrowed Losses
Septerna, Inc. reported a significant increase in Q1 2026 revenue to US$26.52 million from US$219,000 year-over-year, alongside a narrowing net loss to US$8.64 million from US$21.48 million. This positive financial update has led analysts to revise their forecasts for 2026, indicating increased confidence in the company's progress, though Septerna still needs to demonstrate long-term viability beyond initial revenue growth. Investors are cautioned to consider the company's ongoing unprofitability and reliance on successful trial readouts despite the recent gains.
Why Septerna (SEPN) Is Up 11.6% After Q1 Revenue Surge And Narrowed Losses
Septerna, Inc. reported a significant increase in Q1 2026 revenue to US$26.52 million from US$219,000 year-over-year, alongside a reduction in net loss to US$8.64 million. This strong financial performance, driven by a deal with Novo Nordisk and other revenue streams, has led analysts to raise revenue forecasts and trim loss expectations, boosting confidence in the company's progress and its GPCR platform. However, despite the positive trends, analysts maintain an unchanged consensus price target, and the company still faces the challenge of converting early revenue into a durable, clinically de-risked business, with warnings about a potentially optimistic share price valuation.
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) reported a Q1 loss of $0.19 per share, exceeding the Zacks Consensus Estimate of a $0.51 loss, and revenues of $26.52 million, beating estimates by 32.93%. Despite beating earnings and revenue expectations in Q1, the company has underperformed the market year-to-date, with its stock declining 14.4% compared to the S&P 500's 8.1% gain. The current Zacks Rank for SEPN is #4 (Sell), suggesting potential underperformance in the near future.
Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported And Analysts Are Boosting Their Estimates
Septerna, Inc. (NASDAQ:SEPN) exceeded first-quarter revenue and loss expectations, leading analysts to significantly increase revenue forecasts for 2026 and reduce estimated losses. Despite the improved outlook, the consensus price target remained unchanged, suggesting continued analyst concern over ongoing losses. The company's revenue growth is expected to slow but still outpace the broader industry.
Earnings Update: Septerna, Inc. (NASDAQ:SEPN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Septerna, Inc. (NASDAQ:SEPN) reported strong first-quarter results, with revenues significantly exceeding analyst forecasts, while statutory losses were smaller than expected. Following these results, analysts have updated their 2026 forecasts, increasing revenue estimates to US$87.9m but also predicting larger losses of US$2.30 per share. Despite the updated forecasts, the consensus price target remains unchanged at US$44.25, reflecting the analysts' view that growing revenues are offsetting concerns about increased losses.
H.C. Wainwright reiterates Septerna stock rating at buy, $40 target
H.C. Wainwright has reiterated a Buy rating and a $40 price target for Septerna Inc. (NASDAQ: SEPN) following positive Phase 1 trial results for its oral small molecule SEP-631. The drug demonstrated good tolerability and efficacy, with the company planning to initiate a Phase 2b trial in chronic spontaneous urticaria in late 2026. Septerna also has another drug, SEP-479, in Phase 1 trials for hypoparathyroidism, with top-line data expected in late 2026 or early 2027.
Septerna Inc. (SEPN) Stock Price | Live Quotes & Charts | NASDAQ
This NASDAQ page provides live stock quotes and charts for Septerna Inc. (SEPN). It shows the current stock price, which is $24.75 with no change, and indicates that prices are delayed. The page also mentions the absence of analyst ratings and earnings information for Septerna Inc.
H.C. Wainwright reiterates Septerna stock rating at buy, $40 target By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $40 price target for Septerna Inc (NASDAQ:SEPN) following positive Phase 1 trial results for its oral small molecule SEP-631. The drug showed good tolerability and dose-dependent suppression of skin wheal formation, with preparations underway for a Phase 2b trial in chronic spontaneous urticaria. Septerna, a clinical-stage biotech, also reported a strong balance sheet and is progressing with another Phase 1 trial for SEP-479 for hypoparathyroidism.
Septerna (SEPN) Q1 Loss Narrows To US$8.6 Million Challenging Bearish Earnings Narratives
Septerna (SEPN) reported a Q1 2026 revenue of US$26.5 million and narrowed its net loss to US$8.6 million, down from US$10.7 million in Q4 2025. Despite the improved quarterly performance, the company remains unprofitable over the trailing twelve months with a US$36.0 million loss, and analysts forecast continued declines in revenue and earnings over the next three years. Investors are urged to consider the long-term trend, widening losses, and a high P/S ratio compared to the industry average when evaluating the stock.
Wells Fargo Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $48
Wells Fargo has reaffirmed its Buy rating for Septerna (SEPN.US) and maintained its target price at $48. This indicates continued confidence from the financial institution in the company's stock performance.
Septerna, Inc. (SEPN) reports Q1 loss, tops revenue estimates
Septerna, Inc. (SEPN) announced its Q1 financial results, reporting a loss per share of $0.66, which was narrower than the anticipated loss of $0.77. The company's revenue for the quarter reached $160,000, significantly exceeding analyst estimates of $40,000. This indicates stronger-than-expected top-line performance despite ongoing losses.
Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration
Septerna's Q1 revenue saw a sharp increase, positively impacted by its collaboration with Novo Nordisk. This news, reported by Refinitiv via Reuters, is brief and highlights the financial success stemming from the partnership. Readers are prompted to log in or create an account to view the full details.
Septerna, Inc. 1Q 2026: Revenue $26.5M, EPS $(0.19) — 10-Q Summary
Septerna, Inc. reported its first-quarter 2026 financial results, with revenue reaching $26.5 million, significantly up from $0.2 million in Q1 2025, primarily due to research services under its Novo collaboration. The company narrowed its net loss to $(8.6) million and achieved a diluted loss per share of $(0.19). Septerna also highlighted key business developments, including the dosing of first participants in a Phase 1 clinical trial and strong liquidity with $522.1 million in cash, expected to fund operations into 2029.
Septerna moves chronic hives pill toward Phase 2 after Phase 1 study
Septerna (Nasdaq: SEPN) announced its first-quarter 2026 financial results, reporting a narrowed net loss of $8.6 million and $26.5 million in collaboration revenue. The company highlighted positive Phase 1 clinical data for SEP-631, supporting its advancement into Phase 2b for chronic spontaneous urticaria, and the initiation of a Phase 1 trial for SEP-479 for hypoparathyroidism. Septerna projects its $522.1 million cash reserves will fund operations until at least 2029, even as R&D and G&A expenses increased to support pipeline progress.
Earnings Flash (SEPN) Septerna, Inc. Reports Q1 Revenue $26.5M, vs. FactSet Est of $17.0M
Septerna, Inc. (SEPN) has reported its Q1 revenue, reaching $26.5 million. This figure significantly exceeded FactSet's estimated revenue of $17.0 million for the quarter. The announcement highlights a strong financial performance for the biotechnology company.
HC Wainwright & Co. Maintains Septerna (SEPN) Buy Recommendation
This article indicates that HC Wainwright & Co. has reiterated its Buy recommendation for Septerna (SEPN). The firm's consistent positive outlook suggests confidence in the company's future performance. However, the provided content is empty, so no further details are available.
Septerna to Present at Bank of America Securities Health Care Conference
Septerna, Inc., a clinical-stage biotechnology company, announced that its CEO and co-founder, Jeffrey Finer, M.D., Ph.D., will present at the Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 12, 2026, at 5:00 p.m. PT in Las Vegas, with a live webcast available on the company's investor relations website. Septerna focuses on GPCR drug discovery, utilizing its Native Complex Platform® to develop novel small molecule drug candidates across various therapeutic areas.
Septerna, Inc. ($SEPN) CEO 2025 Pay Revealed
Septerna, Inc.'s CEO, Jeffrey Finer, M.D., Ph.D, is estimated to receive $2,933,339 in compensation for 2025, a 60.92% decrease from 2024. This estimate is based on a recent SEC DEF14A filing. The article also provides details on insider trading activity, institutional investor holdings, analyst ratings, and price targets for $SEPN stock.
Stifel Maintains Septerna(SEPN.US) With Buy Rating, Maintains Target Price $43
Stifel has reiterated its Buy rating for Septerna (SEPN.US) and maintained its target price at $43. This indicates continued confidence from the firm in the company's prospects.
Septerna (NASDAQ:SEPN) Now Covered by Stifel Nicolaus
Stifel Nicolaus has initiated coverage on Septerna (NASDAQ:SEPN) with a "Buy" rating and a $43.00 price target, suggesting a potential upside of over 80%. This new coverage contributes to a "Moderate Buy" consensus among analysts, though opinions vary with price targets ranging from $38 to $60. Septerna, a clinical-stage biotechnology company focused on GPCR-based drug discovery, is currently loss-making and has seen recent insider stock sales.
Septerna, Inc. (NASDAQ:SEPN) Sees Significant Growth in Short Interest
Short interest in Septerna, Inc. (NASDAQ:SEPN) increased by 12.9% in April, reaching 2,457,303 shares, representing 5.7% of its shares sold short. Despite recent negative earnings and insider selling, analysts maintain a "Moderate Buy" consensus with an average target price of $43.14. The company develops small molecule drugs targeting G protein-coupled receptors (GPCRs) for various therapeutic areas.
Septerna (NASDAQ: SEPN) details 2026 vote on directors and auditor
Septerna, Inc. (NASDAQ: SEPN) has issued a definitive proxy statement (DEF 14A) detailing the agenda for its upcoming 2026 Annual Meeting of Stockholders. The virtual-only meeting will be held on June 26, 2026, at 2:00 p.m. Pacific Time, where shareholders will vote on the election of two Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The board of directors recommends voting "FOR" both proposals.
Stifel Initiates Septerna(SEPN.US) With Buy Rating, Announces Target Price $43
Stifel has initiated coverage of Septerna (SEPN.US) with a Buy rating. The firm has set a price target of $43 for the stock. This new rating suggests a positive outlook and potential upside for Septerna.
Septerna, Inc. (SEPN) reports Q4 loss, tops revenue estimates
Septerna, Inc. (SEPN) announced its financial results for the fourth quarter, reporting a loss per share of $2.20, which is wider than analyst expectations of a $0.80 loss. Despite the deeper loss, the company surpassed revenue estimates, posting $2.2 million against an anticipated $1.5 million. The report likely includes management's outlook and details on upcoming earnings calls or events.
Top Executives at Septerna, Inc. Make Bold Stock Purchases!
Top executives at Septerna, Inc. (SEPN) recently made significant stock purchases, demonstrating confidence in the company's future despite recent setbacks. SVP, COO & CFO Gil Labrucherie bought 10,000 shares for $56,866, and CEO Jeffrey Finer acquired 17,000 shares for $96,860. These purchases occurred even after Wells Fargo downgraded SEPN due to the discontinuation of a clinical trial, though the company maintains a strong financial position from its IPO.
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna
Novo Nordisk, a leading pharmaceutical company known for its weight-loss treatments, has acquired Septerna, a biotech firm, for $2.2 billion. This strategic move aims to bolster Novo Nordisk's pipeline in obesity pills, indicating a strong focus on expanding its oral medication offerings in the competitive weight-loss market. The acquisition highlights the increasing investment in developing innovative treatments for obesity.
Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial?
Septerna, Inc. has initiated a Phase 1 trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism, marking its second wholly-owned program in clinical development. This trial assesses safety, tolerability, and pharmacokinetics, potentially enrolling up to 150 participants. While SEP-479's readout is anticipated in 2026 or 2027, the trial modestly de-risks Septerna's platform narrative but highlights ongoing risks such as high cash burn and a premium valuation.
Analysts Offer Insights on Technology Companies: Vicor (VICR), Ceragon Networks (CRNT) and Septerna, Inc. (SEPN)
Three analysts from Roth MKM and Truist Financial have issued bullish ratings for technology companies Vicor (VICR), Ceragon Networks (CRNT), and Septerna, Inc. (SEPN). The analysts, Justin Clare, Scott Searle, and Srikripa Devarakonda, all maintained Buy ratings with specific price targets. The consensus for all three stocks is a Strong Buy, indicating potential upside from current levels.
Is Septerna (SEPN) Quietly Redefining Its GPCR Strategy With This First-in-Human SEP-479 Trial?
Septerna, Inc. has initiated a Phase 1 trial for SEP-479, an oral PTH1R agonist for hypoparathyroidism, marking its second wholly owned program in clinical development. This trial advances Septerna's GPCR-targeted pipeline and supports its strategy of developing medicines from its platform. While key near-term catalysts involve SEP-631 and its collaboration with Novo Nordisk, the SEP-479 trial subtly de-risks the platform but also highlights ongoing risks like high cash burn and premium valuation.
Analysts Offer Insights on Technology Companies: Vicor (VICR), Ceragon Networks (CRNT) and Septerna, Inc. (SEPN)
Three analysts have issued bullish sentiments on technology companies Vicor (VICR), Ceragon Networks (CRNT), and Septerna, Inc. (SEPN). Roth MKM reiterated a Buy rating on Vicor with a $245.00 price target and on Ceragon Networks with a $3.75 price target. Truist Financial maintained a Buy rating on Septerna, Inc., which also received an upgrade from TipRanks – PerPlexity to Buy.
Truist Financial Maintains Septerna(SEPN.US) With Buy Rating
Truist Financial has reiterated its Buy rating on Septerna (SEPN.US). The article provides no additional details beyond this information.
Are Options Traders Betting on a Big Move in Septerna Stock?
This article from MSN discusses whether options traders are anticipating significant movement in Septerna stock. It focuses on the activity of options contracts as an indicator of potential future volatility or price changes for the company.
Are Options Traders Betting on a Big Move in Septerna Stock?
The article discusses the recent options trading activity in Septerna stock, indicating that significant call and put options have been bought, suggesting that some traders are anticipating a substantial price movement in the near future. It highlights that this options behavior often precedes notable stock volatility.
Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of "Moderate Buy" from Analysts
Septerna, Inc. (NASDAQ:SEPN) has received an average rating of "Moderate Buy" from nine analysts, with a consensus 1-year price target of $43.14. Despite reports of insider selling totaling $2.19 million over the past 90 days and a recent EPS miss, several firms have reiterated "overweight" or "buy" ratings, increasing price targets. The company's stock is currently trading around $26, with a market capitalization of $1.17 billion.
Septerna Inc (SEPN) president and COO sells $97k in stock
Septerna Inc.'s President and COO, Elizabeth Bhatt, sold 3,990 shares of common stock for approximately $97,343, after exercising options to acquire 4,000 shares. This transaction occurred amidst a significant surge in the company's stock price over the past year. Analysts maintain a bullish outlook on SEPN, which remains slightly undervalued, while the company progresses with clinical trials and strong financial performance.
[Form 4] Septerna, Inc. Insider Trading Activity
Septerna, Inc.'s President and COO, Elizabeth Bhatt, recently exercised stock options for 4,000 shares at $6.81 per share and subsequently sold those shares in open-market transactions at average prices between $23.33 and $25.91. These sales were conducted under a pre-arranged Rule 10b5-1 sales plan adopted in October 2025. Following these transactions, Ms. Bhatt directly owns 174,535 shares of common stock.
Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares
Septerna's COO, Elizabeth Bhatt, recently sold 4,000 shares of the company's stock for $97,360, reducing her stake by 2.24%. This follows a previous sale of 4,000 shares in February. The company's stock is currently trading around $26.13, with analysts holding a consensus "Moderate Buy" rating and an average price target of $43.14.
Septerna Inc (SEPN) president and COO sells $97k in stock
Septerna Inc.'s President and COO, Elizabeth Bhatt, sold 3,990 shares of common stock for approximately $97,343, while also exercising options to acquire 4,000 shares. These transactions occurred after the stock surged significantly, and analysts maintain a bullish outlook, with price targets ranging from $35 to $60. The company also reported a narrower-than-expected Q4 loss and initiated a Phase 1 clinical trial for SEP-479, leading to reiterated Buy ratings from several firms.
Assessing Septerna (SEPN) Valuation After First Dosing In SEP-479 Phase 1 Trial
Septerna (SEPN) has initiated its Phase 1 trial for SEP-479, an oral treatment for hypoparathyroidism. Despite a strong long-term share price performance, the stock's recent momentum has cooled, and its valuation, with a Price-to-Sales ratio of 23.6x, appears overvalued compared to industry averages and its estimated fair value. Investors are advised to review the underlying data due to mixed signals regarding its valuation and the inherent risks of early-stage trials.
Septerna (SEPN) price target increased by 34.39% to 46.41
This article reports a significant increase in Septerna's (SEPN) price target. The target has been raised by 34.39% to reach $46.41.
Septerna (SEPN) price target increased by 34.39% to 46.41
This article states that Septerna (SEPN) has seen its price target increased by 34.39%, raising it to 46.41. No further details are provided in the content.
SEPN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40
HC Wainwright & Co. has reiterated a Buy rating for Septerna (SEPN) with a sustained price target of $40.00, indicating a significant upside potential of approximately 71% from its current trading price. Despite the positive analyst outlook, the company faces challenges highlighted by its low GF Score™ of 21/100, primarily due to low profitability and growth, and recent insider selling valued at $2.1 million. Septerna, operating in biotechnology, is focused on developing oral small molecule drugs for various conditions, with a market capitalization of $1.05 billion.
Is Septerna (SEPN) Using Its First PTH1R Trial To Redefine Its GPCR Strategy?
Septerna, Inc. has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist for hypoparathyroidism, marking its second clinical-stage program. This progression is seen as a validation of execution and pipeline expansion, though the company remains unprofitable with a rich price-to-sales multiple after a significant share price increase. Investors should consider the reliance on new capital and early-stage trials, as expert valuations suggest potential overvaluation despite a wide range of fair value estimates.
H.C. Wainwright reiterates Septerna stock rating on trial start By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $40 price target for Septerna Inc. (NASDAQ: SEPN) following the start of its Phase 1 trial for SEP-479, an oral small molecule for hypoparathyroidism treatment. The stock has seen significant growth, surging 285% over the past year, and analysts anticipate further upside with price targets ranging from $35 to $60. Septerna, which also reported a Q4 loss narrower than expected and substantial revenue from a collaboration with Novo Nordisk, expects top-line data from the trial by late 2026 or early 2027.
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Septerna, Inc. has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist, targeting hypoparathyroidism. The trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-479 in healthy volunteers, with data expected in late 2026 or early 2027. This novel therapy aims to provide a once-daily oral treatment option for patients, addressing a significant unmet need compared to current PHT injections or frequent calcium supplements.
SEPTERNA INC - PHASE 1 TRIAL DATA EXPECTED IN LATE 2026 OR EARLY 2027
SEPTERNA INC anticipates releasing Phase 1 trial data in late 2026 or early 2027. This information is derived from a document, indicating the company's projected timeline for initial clinical study results.
Septerna doses first patient in SEP-479 hypoparathyroidism trial By Investing.com
Septerna Inc. has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule drug candidate aimed at treating hypoparathyroidism, a condition characterized by parathyroid hormone deficiency. The trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SEP-479 in up to 150 healthy adult volunteers, with data expected in late 2026 or early 2027. This news follows a significant 304% stock gain for Septerna over the past year, supported by strong financial metrics and positive preclinical results for SEP-479, which normalized serum calcium in animal models.
Septerna Begins Phase 1 Trial of Oral SEP-479
Septerna, Inc. has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule designed to treat hypoparathyroidism. This randomized, placebo-controlled study will assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 150 healthy adults, with initial data expected in late 2026 or early 2027. The company aims for SEP-479 to offer a more convenient alternative to current treatments and has received a 'Buy' rating from one analyst, with a $38.00 price target on the stock.
